05/26/2026
Quantum BioPharma recently announced a key midpoint milestone in its separate collaborative imaging study with Massachusetts General Hospital, centered on [¹⁸F]3F4AP PET imaging to help assess demyelination in Multiple Sclerosis.
While this study is separate from Lucid-MS trials, we believe this type of imaging research could one day help support the broader scientific understanding of how demyelination is measured and tracked in MS research.
Lucid-MS has completed prior Phase 1 clinical development, and Quantum BioPharma has submitted an IND application to the FDA for a Phase 2 clinical trial.
As Quantum BioPharma’s lead investigational candidate, Lucid-MS was designed to target neurodegenerative pathways linked to the citrullination cascade, representing a differentiated scientific approach from traditional immunomodulatory therapies.
Learn more in our May 18, 2026 news release.
https://www.globenewswire.com/news-release/2026/05/18/3296317/0/en/quantum-biopharma-reaches-key-midpoint-milestone-in-groundbreaking-imaging-study-with-massachusetts-general-hospital.html
$QNTM